Oncoteq is a clinical stage biotech focusing on oncology drug development reinforced by AI. It is founded and seeded by Cureteq and headquartered in Zug, Switzerland. The company is expanding the pipeline which currently comprises TEQ101 as a novel treatment option for advanced renal cell cancer with broad potential to expand into other indications.
TEQ102
CD30
CD30+ Lymphomas
TEQ103
ER alpha
Breast cancer